Rolapitant Hydrochlorid Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 90 mg

Reference Brands: Varubi(USA/LATAM), Varuby(EU)

Category: Critical Care

Product Description:

Rolapitant hydrochloride is an orally administered, selective neurokinin-1 (NK1) receptor antagonist with potent antiemetic activity, primarily used to prevent chemotherapy-induced nausea and vomiting (CINV) in adult patients receiving moderately or highly emetogenic cancer therapy. The drug works by competitively binding to NK1 receptors in the central nervous system, thereby blocking the activity of substance P, a key neuropeptide responsible for triggering nausea and vomiting. By inhibiting this pathway, rolapitant helps prevent both acute and delayed emesis associated with cancer chemotherapy.

Rolapitant distinguishes itself from other NK1 receptor antagonists through its rapid onset of action and extended half-life, allowing for effective, long-lasting protection against CINV with a single oral dose. It is typically administered in combination with other antiemetic agents, such as 5-HT3 receptor antagonists and corticosteroids, to maximize patient comfort and adherence to cancer treatment regimens.

As a centrally acting antiemetic, rolapitant provides an important supportive care option for oncology patients, improving quality of life during chemotherapy by reducing the burden of nausea and vomiting and allowing patients to better tolerate their prescribed cancer therapy.